from Sachiko Seo and Michael Boeckh writing in Cytomegaloviruses: From Molecular Pathogenesis to Intervention:
HCMV infection remains an important complication after hematopoietic cell transplantation (HCT), although significant progress in the management of HCMV infection and disease has been made in the last two decades. A major achievement has been the optimization of preemptive therapy strategies based on surveillance by the pp65 antigenemia assay or HCMV DNA or RNA detection. However, current strategies are limited by the toxicity of antiviral agents and breakthrough disease in highly immunosuppressed individuals. Antiviral resistance occurs infrequently after HCT, but can be a considerable management challenge. This review outlines the current topics in host immunity, diagnosis, prevention, treatment of HCMV disease in HCT recipients, and future directions of HCMV management.
Further reading: Cytomegaloviruses: From Molecular Pathogenesis to Intervention